|1.||Guichard, Sylvie M: 5 articles (11/2014 - 04/2012)|
|2.||Guichard, Sylvie: 4 articles (02/2013 - 01/2010)|
|3.||Wei, Feng: 2 articles (01/2015 - 01/2013)|
|4.||Liu, Yan: 2 articles (01/2015 - 01/2013)|
|5.||Wang, Guangyi: 2 articles (01/2015 - 01/2013)|
|6.||Marignani, Paola A: 2 articles (12/2014 - 01/2013)|
|7.||Andrade-Vieira, Rafaela: 2 articles (12/2014 - 01/2013)|
|8.||Logie, Armelle: 2 articles (06/2014 - 04/2012)|
|9.||Zhou, Yong-Qing: 2 articles (05/2014 - 01/2014)|
|10.||Yao, Hang-Ping: 2 articles (05/2014 - 01/2014)|
06/01/2012 - "Finally, AZD8055 markedly increased the survival of AML transplanted mice through a significant reduction of tumor growth, without apparent toxicity. "
01/01/2015 - "Therefore, targeting of the mTOR pathway is an attractive strategy for cancer treatment and several mTOR inhibitors, including AZD8055 (AZD), a novel dual mTORC1/2 inhibitor, are currently in clinical trials. "
06/01/2013 - "This is the first phase I, dose-finding study of AZD8055, a first-in-class dual mTORC1/2 inhibitor, in Japanese patients with advanced solid tumors. "
06/01/2013 - "Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study."
12/30/2014 - "Treatment of LKB1-/-NIC mice with AZD8055 and 2-DG mono-therapies significantly reduced mammary gland tumorigenesis by inhibiting mTOR pathways and glycolytic metabolism; however simultaneous inhibition of these pathways with AZD8055/2-DG combination was significantly more effective at reducing tumor volume and burden. "
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
01/01/2013 - "Our data provide a rationale for overcoming radio-resistance by combined with mTOR inhibitor AZD8055 in pancreatic cancer therapy."
01/01/2015 - "This study provides a rationale and strategy for overcoming AZD8055 resistance by a combined treatment with the EGFR inhibitor erlotinib in pancreatic cancer therapy. "
01/01/2014 - "Combination of BMS-777607 with AZD8055 achieves the maximal cytotoxic effect on pancreatic cancer and cancer stem cells."
01/01/2014 - "Here, we report the synergistic activity of BMS-777607 in combination with mTOR inhibitor AZD8055 in killing chemoresistant pancreatic cancer and cancer stem cells. "
01/01/2013 - "In human pancreatic cancer xenografts, fractionated radiation combined with AZD8055 treatment further increased the anti-tumor effect, the tumor volume was shrinked to 278 mm3 after combination treatment for 3 weeks compared with single radiation (678 mm3) or AZD8055 (708 mm3) treatment (P < 0.01). "
11/01/2014 - "Our study suggests that combination treatment with AZD8055 and IGF1R-blocking agents is a promising strategy in multiple myeloma with potential IGF1R/Akt signaling-mediated survival."
11/01/2014 - "AZD8055 treatment, however, induced upregulation of IGF1R phosphorylation in p-Akt S(473)-expressing multiple myeloma cell lines. "
11/01/2014 - "Unlike rapamycin, AZD8055 resulted in apoptosis of multiple myeloma cells. "
11/01/2014 - "We next validated AZD8055 inhibition of mTORC1 and mTORC2 functions in multiple myeloma cells alone or in culture with bone marrow stroma cells and growth factors. "
11/01/2014 - "We evaluated p-mTOR S(2481) as the readout for mTORC2/Akt activity in multiple myeloma cells in the context of mTOR inhibition via AZD8055 or rapamycin. "
|4.||Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
03/29/2011 - "Here, we define the effectiveness of specific mTOR (AZD8055) and PI3K (GDC-0941) inhibitors, currently in clinical trials, in treating spontaneous B-cell follicular lymphoma that develops in PTEN(+/-)LKB1(+/hypo) mice. "
03/29/2011 - "The PTEN(+/-)LKB1(+/hypo) mice were administered AZD8055 or GDC-0941, and the volumes of B-cell follicular lymphoma were measured by MRI. "
09/25/2012 - "Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma."
09/25/2012 - "Patients with advanced solid malignancies or lymphomas were recruited into this phase I, open-label, dose-escalation study of AZD8055 starting at 10 mg twice-daily oral dosing (BID). "
|3.||Dihydrotachysterol (AT 10)
|4.||erlotinib (CP 358,774)
|6.||Adenosine Triphosphate (ATP)
|7.||DNA (Deoxyribonucleic Acid)
|8.||N- (4- (2- amino- 3- chloropyridin- 4- yloxy)- 3- fluorophenyl)- 4- ethoxy- 1- (4- fluorophenyl)- 2- oxo- 1,2- dihydropyridine- 3- carboxamide
|9.||Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
|10.||JNK Mitogen-Activated Protein Kinases
|1.||Heterologous Transplantation (Xenotransplantation)